Clinical Trials

1,096 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01274338 2026-05-05

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Melanoma

NCT02506153 2026-05-04

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Melanoma

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04008030 2025-10-03

CheckMate 8HW

839 enrolled 22 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT02872116 2025-08-07

CheckMate649

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04026412 2025-07-24

CheckMate73L

925 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT03141177 2025-06-06

CheckMate 9ER

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

945 enrolled 19 charts

Melanoma

NCT02785952 2025-05-21

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

275 enrolled 15 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02388906 2025-04-24

CheckMate 238

906 enrolled 16 charts 1 FDA

Melanoma

NCT02017717 2025-04-04

CheckMate 143

529 enrolled 28 charts

CNS

Glioblastoma

NCT03138512 2024-12-18

CheckMate 914

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04340193 2024-11-26

CheckMate 74W

26 enrolled 15 charts

Gastrointestinal

Liver Neoplasms

NCT02899299 2024-05-21

CheckMate743

605 enrolled 17 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02864251 2023-09-28

CheckMate722

367 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03302234 2023-09-26

KEYNOTE-598

568 enrolled 20 charts

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02741570 2023-09-21

CheckMate 651

947 enrolled 19 charts

Head & Neck

Head and Neck Neoplasms

NCT02538666 2023-01-05

CheckMate 451

907 enrolled 17 charts

Lung Neoplasms

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 3 Terminated

481 enrolled 22 charts

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02714218 2022-06-24

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

387 enrolled 28 charts

Melanoma

NCT03068455 2021-09-20

CheckMate 915

1,844 enrolled 14 charts

Melanoma

NCT02599402 2021-06-15

CheckMate 401

533 enrolled 19 charts

Melanoma

NCT02905266 2020-12-17

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

106 enrolled 20 charts

Melanoma

NCT01450761 2020-07-08

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

1,351 enrolled 10 charts

Small Cell Lung Carcinoma

NCT01285609 2020-06-18

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

1,289 enrolled 14 charts

Lung Cancer - Non Small Cell Squamous

NCT01866319 2020-06-02

MK-3475-006

834 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02545075 2020-05-19

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

182 enrolled 20 charts

Melanoma

NCT02279732 2019-08-28

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

342 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01515189 2019-07-31

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

831 enrolled 16 charts

Melanoma

NCT00861614 2016-09-30

Study of Immunotherapy to Treat Advanced Prostate Cancer

988 enrolled 19 charts

Prostatic Neoplasms

NCT01057810 2016-08-18

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

837 enrolled 15 charts

Prostatic Neoplasms

NCT00324155 2014-11-03

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

681 enrolled 24 charts

Melanoma

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

1,783 enrolled 29 charts